Abstract
Radial glial cells represent a subpopulation of secondary neural precursor cells that differentiate from neuroepithelial progenitors and are transiently found in the developing CNS of mammals. There is ample evidence for a temporal and spatial arrangement of increasingly committed radial glial cells that is of critical importance for the organisation and specification of different brain regions. For the human ganglionic eminence, recent findings have shown an early molecular specification of this cell type by the CD15 carbohydrate epitope, beginning already at the end of the first trimester. Here we further characterise the CD15+ radial glia cells as bFGF/EGF responsive progenitors allowing its propagation in vitro. By magnet activated cell sorting, its trilineage differentiation potential can be shown by differentiation into (PSANCAM ß3 tubulin immunoreactive) neurones, GFAP expressing cells of astrocytic morphology, and O4 positive oligodendrocytes. Subcloning experiments under proliferation conditions reveal ongoing CD15 expression by dividing cells. Although the relative number of CD15+ progenitor cells is found to decrease in favour of CD15- precursor cells during continuous passaging, cell sorting experiments allow the repetitive purification of high numbers of positively selected precursor cells for up to 12 weeks. In conclusion, expression of the cell adhesion molecule CD15 by a subpopulation of proliferative cells from the lateral ganglionic eminence allows easy and reproducible purification of progenitor cells by cell sorting, enabling the generation of a compartment-specific cell pool as a prerequisite for a safe and standardised therapy of neurodegenerative basal forebrain diseases.
Keywords: Ganglionic eminence, radial glia, CD15, progenitor cells
Current Pharmaceutical Biotechnology
Title:Clonogenic CD15 Immunoreactive Radial Glial Cells from the Developing Human Lateral Ganglionic Eminence
Volume: 14 Issue: 1
Author(s): Dajana Buttler, Jurgen K. Mai, Ken W.S. Ashwell and Christian Andressen
Affiliation:
Keywords: Ganglionic eminence, radial glia, CD15, progenitor cells
Abstract: Radial glial cells represent a subpopulation of secondary neural precursor cells that differentiate from neuroepithelial progenitors and are transiently found in the developing CNS of mammals. There is ample evidence for a temporal and spatial arrangement of increasingly committed radial glial cells that is of critical importance for the organisation and specification of different brain regions. For the human ganglionic eminence, recent findings have shown an early molecular specification of this cell type by the CD15 carbohydrate epitope, beginning already at the end of the first trimester. Here we further characterise the CD15+ radial glia cells as bFGF/EGF responsive progenitors allowing its propagation in vitro. By magnet activated cell sorting, its trilineage differentiation potential can be shown by differentiation into (PSANCAM ß3 tubulin immunoreactive) neurones, GFAP expressing cells of astrocytic morphology, and O4 positive oligodendrocytes. Subcloning experiments under proliferation conditions reveal ongoing CD15 expression by dividing cells. Although the relative number of CD15+ progenitor cells is found to decrease in favour of CD15- precursor cells during continuous passaging, cell sorting experiments allow the repetitive purification of high numbers of positively selected precursor cells for up to 12 weeks. In conclusion, expression of the cell adhesion molecule CD15 by a subpopulation of proliferative cells from the lateral ganglionic eminence allows easy and reproducible purification of progenitor cells by cell sorting, enabling the generation of a compartment-specific cell pool as a prerequisite for a safe and standardised therapy of neurodegenerative basal forebrain diseases.
Export Options
About this article
Cite this article as:
Buttler Dajana, K. Mai Jurgen, W.S. Ashwell Ken and Andressen Christian, Clonogenic CD15 Immunoreactive Radial Glial Cells from the Developing Human Lateral Ganglionic Eminence, Current Pharmaceutical Biotechnology 2013; 14 (1) . https://dx.doi.org/10.2174/1389201011314010006
DOI https://dx.doi.org/10.2174/1389201011314010006 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cerebral Microbleeds and White Matter Hyperintensities are Associated with Cognitive Decline in an Asian Memory Clinic Study
Current Alzheimer Research The Endocannabinoid System in Peripheral Lymphocytes as a Mirror of Neuroinflammatory Diseases
Current Pharmaceutical Design Transcriptional Dysregulation in Huntington’s Disease: The Role in Pathogenesis and Potency for Pharmacological Targeting
Current Medicinal Chemistry Neuroimaging Features of Acquired Metabolic and Toxic Encephalopathies
Current Medical Imaging Volumetric Changes in the Basal Ganglia After Antipsychotic Monotherapy: A Systematic Review
Current Medicinal Chemistry Alpha7 Neuronal Nicotinic Receptor: A Pluripotent Target for Diseases of the Central Nervous System
CNS & Neurological Disorders - Drug Targets Military Risk Factors for Cognitive Decline, Dementia and Alzheimer’s Disease
Current Alzheimer Research Neurokinin 3 (NK3) Receptor Modulators for the Treatment of Psychiatric Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Glutamate Receptors as Therapeutic Targets for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Ezrin Expression is Increased During Disease Progression in a Tauopathy Mouse Model and Alzheimer’s Disease
Current Alzheimer Research Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets Translational Methods for Non-Invasive Electrical Stimulation to Facilitate Gait Rehabilitation Following Stroke - The Future Directions
Neuroscience and Biomedical Engineering (Discontinued) PET Radiotracers for Molecular Imaging of Serotonin 5-HT<sub>1A</sub> Receptors
Current Medicinal Chemistry A Role of GABA Analogues in the Treatment of Neurological Diseases
Current Medicinal Chemistry Cerebral Hypoperfusion in Hereditary Coproporphyria (HCP): A Single Photon Emission Computed Tomography (SPECT) Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Myopathic Involvement and Mitochondrial Pathology in Kennedy Disease and in Other Motor Neuron Diseases
Current Molecular Medicine The Integration of the Glutamatergic and the White Matter Hypotheses of Schizophrenias Etiology
Current Neuropharmacology Gut Permeability and Microbiota in Parkinson’s Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways
Current Pharmaceutical Design PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia
Current Pharmaceutical Design The Antioxidant Response as a Drug Target in Diabetic Neuropathy
Current Drug Targets